Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Datamonitor
|
$175.00
|
|
Trading Report for (NVS). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: Market Edge
|
$10.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Novartis AG's Drug Afinitor Gets EU Nod For Breast Cancer-Reuters
Reuters reported that Novartis AG's drug Afinitor, was approved by European regulators to treat women with a certain type of breast cancer. The drug is known as mTOR inhibitors to be approved for post menopausal women with advanced hormone receptor positive, HER2-negative breast cancer. American health regulators also backed the drug as a breast cancer treatment. Afinitor, also known as everolimus, is designed to be given in combination with another drug, Aromasin, to treat women whose cancer has recurred or progressed after treatment with two other therapies.
Latest Developments for Novartis AG
- Novartis AG's Drug Ilaris Approved By FDA To Treat Active Systemic Juvenile Idiopathic Arthritis
- Pfizer Inc, Novartis AG And Abbott Laboratories Weigh Bids For Brazil's Ache Laboratorios Farmaceuticos-Reuters
- UK Cost Body Rejects Novartis AG's Breast Cancer Drug-Reuters
- UK Cost Agency Says No To Novartis AG's Blood Cancer Drug Jakavi-Reuters
Latest Key Developments in Pharmaceuticals
- Share this
- Link this
- Digg this
Follow Reuters